Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales

Merck reported first-quarter revenue and adjusted earnings that topped expectations as it posted strong sales of its blockbuster cancer drug Keytruda and vaccine products.

The company expects full-year adjusted earnings of $8.53 to $8.65 per share, up from its prior forecast of $8.44 to $8.59 per share.of Harpoon Therapeutics in January. The company develops immune-based cancer drugs. The guidance also includes a negative impact of 30 cents per share from foreign exchange changes.

Excluding acquisition and restructuring costs, Merck earned $2.07 per share for the first quarter. Both adjusted and non-adjusted profit for the period include the charge related to the Harpoon deal.patent expiration Merck is also cutting costs under a new restructuring program it announced in February. Those efforts aim to improve the manufacturing network of both its pharmaceutical division and animal health business.

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

Stocks making the biggest moves premarket: Robinhood, GameStop, Merck and moreThese are the stocks posting the largest moves in premarket trading.
출처: CNBC - 🏆 12. / 72 더 많은 것을 읽으십시오 »

Stocks making the biggest moves midday: GameStop, Merck, Carnival, Cintas and moreThese are the stocks posting the largest moves in midday trading.
출처: CNBC - 🏆 12. / 72 더 많은 것을 읽으십시오 »

Cramer's week ahead: Earnings from Tesla, Merck and Big TechCNBC’s Jim Cramer said next week’s PCE index report will be the real gauge of inflation.
출처: NBCLA - 🏆 319. / 59 더 많은 것을 읽으십시오 »

Cramer’s week ahead: Earnings from Tesla, Merck and Big TechCNBC's Jim Cramer said next week's PCE index report will be the real gauge of inflation.
출처: CNBC - 🏆 12. / 72 더 많은 것을 읽으십시오 »